[1]柳鹏程,李 灿,杜 怿,等.中国医保预算影响分析的研究范式[J].卫生经济研究,2021,38(1):40-46.
　LIU Peng-cheng,LI Can,DU Yi,et al.Research Paradigm of Impact Analysis on Medical Insurance Budget in China[J].Journal Press of Health Economics Research,2021,38(1):40-46.
点击复制

中国医保预算影响分析的研究范式

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年1期
页码:
40-46
栏目:
医保天地
出版日期:
2021-01-07

文章信息/Info

Title:
Research Paradigm of Impact Analysis on Medical Insurance Budget in China
作者:
柳鹏程1; 李 灿1; 杜 怿1; 方 刚1; 王敏娇1; 姚文兵1
1.中国药科大学， 江苏 南京 211198
Author(s):
LIU Peng-cheng; LI Can; DU Yi; FANG Gang; WANG Min-jiao; YAO Wen-bing
China Pharmaceutical University,Nanjing Jiangsu 211198,China
关键词:
医疗保险; 预算影响分析; 研究范式
Keywords:
medical insurance; budget impact analysis; research paradigm
分类号:
R19
文献标志码:
A
摘要:
目的：探索中国医保预算影响分析研究范式，为规范研究框架和研究过程、提高研究结论的可靠性，提供理论和经验依据。方法：通过文献研究，了解医保预算影响分析研究的模型设计、关键要素、数据需求等理论方法及最新发展动态，结合中国国情，总结归纳适合中国的医保预算影响分析研究范式。结果：医保预算影响分析应包括模型设计、研究角度、市场情景、目标人群、研究时限、治疗成本、不确定性分析7大关键要素；此外，医保预算影响分析报告还应包括计算所用数据集、数据来源，并附计算软件与运算过程，以便于医保主管部门审查验证。结论：医保预算影响分析能够评价短期、特定情景内药物进入医保目录对医保基金的影响，与药物经济学配合使用服务于医保决策。
Abstract:
Objective To explore the research paradigm of impact analysis on health insurance budget in China,provide theoretical and empirical basis for standardizing the research framework and research process,and improving the reliability of research conclusions.Methods The literature review method was used to understand the model design,key elements,data requirements and other theoretical methods and the latest development trends of health insurance budget impact analysis，and summarize the research paradigm of health insurance budget impact analysis suitable combined with Chinese situation.Results The impact analysis of health insurance budget should include seven key elements:model design, research perspective,market situation, target population,research duration, treatment cost and uncertainty analysis.In addition, the health insurance budget impact analysis report should include the data set and data sources used for calculation,together with calculation software and calculation process, so as to facilitate the examination and verification of the medical insurance department.Conclusion The impact analysis of health insurance budget can evaluate the influence of drugs entering health insurance catalogue in short-term and specific scenarios on health insurance fund, and can be used with pharmaco economics to serve health insurance decision-making.

参考文献/References:

[1] Ghabri S,Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England,France and the United States:relationship to cost-effectiveness analysis and methodological challenges[J].European Journal of Health Economics, 2018,19(4):1-3.
[2] 董雅琦，顾佳慧，柳鹏程.医保预算影响分析国际经验研究及对我国的启示[J].中国药房，2018，29（12）：1652-1657.
[3] Sullivan S D, Mauskopf J A, Federico A, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force[J].Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research,2014,17(1):5-14.
[4] Mauskopf J, Earnshaw S. A Methodological Review of US Budget-Impact Models for New Drugs[J].PharmacoEconomics,2016,34(11):1111-1131.
[5] Mauskopf J A, Stephanie E, C Daniel M. Budget impact analysis: review of the state of the art[J].Expert Review of Pharmacoeconomics & Outcomes Research,2005,5(1):65-79.
[6] Authority H I A Q.Guidelines for the Budget Impact Analysis of Health Technologies in Ireland[EB/OL].https://www.hiqa.ie/sites/default /files/2018-01/HIQA_BIA_Guidelines_2018_0.pdf.,2018.
[7] 俞观文.再谈国家基本药物制度[J].中国制药信息，2007,23(7):1-3.
[8] 顾佳慧，柳鹏程.浅析药物经济学评价与医疗保险预算影响分析的差异[J].中国药物经济学，2018，13（3）：40-44.
[9] Shiragami M.Pharmacoeconomics[J].Cheminform,2003,34(30):133.
[10] Leelahavarong P. Budget impact analysis[J].J Med Assoc Thai, 2014,97 Suppl 5:S65-S71.
[11] Marshall D A D P R D. Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada[J].PharmacoEconomics,2008,26(6):477-495.
[12] Zorman M,tiglic M M, Kokol P,et al.The Limitations of Decision Trees and Automatic Learning in Real World Medical Decision Making[J].Journal of Medical Systems,1997,21(6):403-415.
[13] Welsing P M J,Severens J L,Margriet H, et al. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis[J].Pharmacoeconomics,2006,24(10):1011-1020.
[14] 中国药物经济学评价指南课题组,刘国恩, 胡善联,等.中国药物经济学评价指南（2011版）[S].2011.
[15] Ghabri S,Autin E,Poullié A I,et al.The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)[J].Pharmacoeconomics,2018,36(4):407.
[16] Hilden J.Budget Impact Analysis and Its Rational Basis[J]. Medical Decision Making An International Journal of the Society for Medical Decision Making,2008,28(4):460.
[17] Gazarian M,Kelly M,Mcphee J R,et al.Off-label use of medicines:consensus recommendations for evaluating appropriateness[J].Med J Aust,2006,185(10):544-548.
[18] Orlewska E, Mierzejewski P.Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries[J].Value in Health, 2010,7(1):1-10.
[19] 沈焕根, 张磊.全民医保基金长期平衡运营面临的风险[J].中国医疗保险，2012（2）：22-25.
[20] Claxton K. Exploring Uncertainty in Cost-Effectiveness Analysis[J].Pharmacoeconomics,2008,26(9):781-798.
[21] Briggs A,Sculpher M,Buxton M. Uncertainty in the economic evaluation of health care technologies:the role of sensitivity analysis[J]. Health Econ,1994,3(2):95-104.
[22] Marshall D A,Douglas P R, Drummond M F,et al.Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada[Z].Cham:Adis International,2008: 26,477-495.
[23] 马爱霞，钱焊森，张籍元，等.中国与加拿大预算影响分析研究的研究质量评价[J].中国循证医学杂志，2017，17（10）：1231-1236.
[24] Kuan R, Holt R J,Johnson K E,et al. Budget Impact Modeling for a Single-Tablet Formulation of Ibuprofen and Famotidine for Prevention of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis and/or Rheumatoid Arthritis[J].Clinical Therapeutics, 2013,35(3):321-332.
[25] Nuijten M J C,Mittendorf T,Persson U.Practical issues in handling data input and uncertainty in a budget impact analysis[J].European Journal of Health Economics Hepac Health Economics in Prevention & Care,2011,12(3):231-241.
[26] Mar J,Arrospide A,Comas M.Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation Model[J]. Value in Health, 2010,13(1):69-76.

相似文献/References:

[1]王 翔.取消“两定”审批对医保管理的影响及对策[J].卫生经济研究,2016,(03):56.
[2]赵 云,王政乂.公立医院体制机制与医疗保险付费方式适配的主要模式[J].卫生经济研究,2016,(05):22.
[3]于保荣.医保定点机构管理新政的探讨[J].卫生经济研究,2016,(07):43.
[4]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[5]姜海珊.农民工参加城镇职工医疗保险状况的比较分析[J].卫生经济研究,2016,(12):29.
[6]杨金侠,冀路肖.某省三种基本医疗保险支付方式调查与思考[J].卫生经济研究,2017,(02):39.
[7]胡善联.论美国特朗普新医改计划的前景[J].卫生经济研究,2017,(03):3.
[8]马 雷,柳俊杰,李 军,等.天津市恶性肿瘤医保患者自付状况分析[J].卫生经济研究,2017,(04):50.
[9]袁红梅,何克春,袁维福,等.医院医疗保险费用结算现状及对策研究[J].卫生经济研究,2017,(04):53.
[10]李芳凡,杨超柏.试论生育保险与医疗保险的合并[J].卫生经济研究,2017,(05):50.
[11]杜 怿,李 灿,方 刚,等.医保药物经济性评价质量评估量表研究及启示[J].卫生经济研究,2020,(06):28.
　DU Yi,LI Can,FANG Gang,et al.Research and Enlightenment of Quality Assessment Scale for Medical Insurance Drugs' Economic Evaluation[J].Journal Press of Health Economics Research,2020,(1):28.

更新日期/Last Update: 2021-01-07